Murray E, Cheng X, Krishna A, Jin X, Ohara T, Stappenbeck T, et al. HER2 and APC Mutations Promote Altered Crypt-Villus Morphology and Marked Hyperplasia in the Intestinal Epithelium. Cell Mol Gastroenterol Hepatol. 2021;12:1105-1120 pubmed publisher

Watanabe M, Kuwata T, Setsuda A, Tokunaga M, Kaito A, Sugita S, et al. Molecular and pathological analyses of gastric stump cancer by next-generation sequencing and immunohistochemistry. Sci Rep. 2021;11:4165 pubmed publisher

Christgen M, Bartels S, van Luttikhuizen J, Bublitz J, Rieger L, Christgen H, et al. E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements. Mod Pathol. 2020;33:2483-2498 pubmed publisher

Hryciuk B, Pęksa R, Bieńkowski M, Szymanowski B, Radecka B, Winnik K, et al. Expression of Female Sex Hormone Receptors, Connective Tissue Growth Factor and HER2 in Gallbladder Cancer. Sci Rep. 2020;10:1871 pubmed publisher

Pietila M, Sahgal P, Peuhu E, Jäntti N, Paatero I, Närvä E, et al. SORLA regulates endosomal trafficking and oncogenic fitness of HER2. Nat Commun. 2019;10:2340 pubmed publisher

Doebar S, Sieuwerts A, de Weerd V, Stoop H, Martens J, van Deurzen C. Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer. Am J Pathol. 2017;187:1648-1655 pubmed publisher

Qi L, Zhou L, Lu M, Yuan K, Li Z, Wu G, et al. Development of a highly specific HER2 monoclonal antibody for immunohistochemistry using protein microarray chips. Biochem Biophys Res Commun. 2017;484:248-254 pubmed publisher

Leo F, Bartels S, Mägel L, Framke T, Büsche G, Jonigk D, et al. Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer. Virchows Arch. 2016;469:191-201 pubmed publisher

Song M, Park Y, Song H, Park S, Ahn J, Choi K, et al. Prognosis of Pregnancy-Associated Gastric Cancer: An Age-, Sex-, and Stage-Matched Case-Control Study. Gut Liver. 2016;10:731-8 pubmed publisher

Gómez R, Ossa C, Montoya M, Echeverri C, Ángel G, Ascuntar J, et al. Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy. Ecancermedicalscience. 2015;9:562 pubmed publisher

Thomas G, Chardès T, Gaborit N, Mollevi C, Leconet W, Robert B, et al. HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models. Oncotarget. 2014;5:7138-48 pubmed

Rikhi R, Wilson E, Déas O, Svalina M, Bial J, Mansoor A, et al. Murine model of hepatic breast cancer. Biochem Biophys Rep. 2016;8:1-5 pubmed publisher

Pinder S, Campbell A, Bartlett J, Marshall A, Allen D, Falzon M, et al. Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial. Br J Cancer. 2017;116:859-863 pubmed publisher

Catalano O, Horn G, Signore A, Iannace C, Lepore M, Vangel M, et al. PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype. Br J Cancer. 2017;116:893-902 pubmed publisher